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Background: Trends in the isolation of enteropathogenic bacteria may differ depending 
on environmental sanitation. This study aimed to determine trends in the isolation and 
antimicrobial resistance patterns of enteropathogenic bacteria between 2011 and 2019. 
Methods: A retrospective analysis was performed using data from stool cultures of 
Salmonella spp., Shigella spp., Plesiomonas shigelloides, Yersinia spp., Vibrio spp., and 
Campylobacter spp. The sample was collected at Severance Hospital between 2011 and 
2019. Antimicrobial susceptibility testing was performed using the disk diffusion method 
for nontyphoidal Salmonella (NTS) and Campylobacter spp. following CLSI guideline. 
Results: The number of specimens for stool culture significantly increased from 13,412 
during 1969-1978 to 48,476 over the past nine years, whereas the ratio of positive 
specimens significantly decreased from 1,732 (12.9%) to 449 (0.9%). The proportion of 
Salmonella Typhi decreased from 472 (93.6%) in 1969-1978 to 4 (1.5%) in 2011-2019, 
whereas the proportion of NTS increased from 14 (2.8%) to 261 (96.7%). The proportion 
of Shigella among all enteropathogenic bacteria was 1,039 (60.0%) from 1969-1978, while 
only 7 (1.6%) were isolated from 2011-2019. Campylobacter is the second most prevalent 
organisms, which were isolated 132 (29.4%). The susceptibility rate to ampicillin and 
cotrimoxazole were 51.1% and 85.2%, respectively, for NTS isolated from 2016 -2019. 
The ciprofloxacin susceptibility rate was 15.8% for Campylobacter from 2016-2019. 
Conclusion: The number of isolates of Salmonella Typhi and Shigella significantly 
decreased, while the proportion of NTS and Campylobacter increased. Continuous 
monitoring of ciprofloxacin-resistant Campylobacter isolates is necessary. 





Gastroenteritis refers to stomach and intestinal infections, and most forms of acute 
gastroenteritis are known as acute diarrhea. Diarrhea is commonly characterized as the 
movement of an increased quantity and frequency of abnormally liquid or formless stools. 
It is classified as infectious diarrhea when diarrhea is caused by a source of infection and 
is followed by nausea, vomiting, and abdominal pain. However, in the clinic, the 
microorganism causing the infection is seldom confirmed. Diarrhea is defined as acute if it 
lasts for 14 days or less, which is the case for most infectious diarrhea [1]. 
Diarrheal disease is the second leading cause of morbidity and mortality, and mainly 
occurred in children under 5 years of age, which is one of the global public health issues, 
especially in developing countries. This is so in Asia, Africa and Latin America [1-3]. 
According to the World Health Organization (WHO), were based on 4.6 billion cases of 
diarrhea and 1.6 million deaths due to diarrhea were recorded in 2010 [4, 5]. The most 
frequent pathogens causing acute gastroenteritis worldwide are Salmonella spp., Shigella 
spp., Campylobacter spp., E. coli O157:H7, Listeria monocytogenes, Yersinia 
enterocolitica, Vibrio cholerae, Rotavirus, Entamoeba histolytica, Cryptosporidium spp., 
and Giardia lamblia [1, 6]. Moreover, the diarrhea-causing pathogen depends on factors 
such as the atmosphere, climate, season, and region, so the prevalence of pathogen 
separation in each region must be considered [7]. In developing countries such as 
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Cambodia, Kenya, and Burkina Faso, where diarrhea rates are high due to low income and 
undernutrition, the most frequently isolated pathogens were enteroaggregative E. coli [8-
10], but the most prevalent in Tehran was Shigella [11]. However, many developed 
countries have a high standard of health and hygiene, so enteritis is less likely to develop, 
but infectious diarrhea can also occur in developed countries, as was the case with more 
than 3,000 infections of the Escherichia coli O104: H4 in Germany in May 2011 [3]. In 
addition, Salmonella (56%) and Shigella (21%) were the most commonly detected 
pathogens in Europe and Latin America, as examined by the 2003 global SENTRY 
Antimicrobial Surveillance Program [12]. 
In Korea, 14.7 percent of enteropathogenic bacteria were isolated based on acute infectious 
diarrhea surveillance in 2017. Bacteria have been found not to account for a high 
percentage of cases [1]. In most cases acute gastroenteritis is a self-limiting condition that 
do not require antibiotic treatment. Inappropriate use of antibiotics may cause antibiotic-
associated diarrhea or other complications and may also lead to antibiotic resistance in the 
long term [1]. With the continuous improvement of health and hygiene, the incidence of 
infectious enteritis is decreasing, but the resistance rate of infectious enteritis is increasing. 
In addition, the increase in overseas travel has increased the likelihood of the introduction 
or epidemic of infectious enteritis caused by contaminated food or water [6, 7]. 
However, studies in South Korea over the past 10 years have primarily focused on 
advanced genotypic and phenotypic characteristics of enteropathogenic bacteria and as a 
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result very few studies have been done on conventional surveillance of these pathogens 
leading to a gap in data for monitoring the trends in isolation and resistance patterns. 
Conventional method, however, remains as a gold standard for the confirmation of bacteria 
to monitor the trend and resistance patterns of enteropathogenic bacteria. 
1.2 Aim of study 
This study aims to determine the trends in the isolation and antimicrobial resistance patterns 
of enteropathogenic bacteria between 2011 and 2019 at Severance Hospital. Also, to 
compare the current pattern and trends of enteropathogenic bacteria’s antimicrobial 
susceptibility with previous results in Severance Hospital. 
1.3 Significance 
This research will therefore be useful in providing clinical guidelines based on the latest 
evidence of scientific antibiotic therapy for suspected acute gastroenteritis usually seen in 
clinics and targeted antibiotic therapy for reported bacterial growth cases, with the aim of 




II. LITERATURE REVIEW  
2.1 Common Enteropathogenic Bacteria 
Many types of enteropathogenic bacteria cause acute gastroenteritis, and these types are 
different according to regions. In the following part, we will discuss the isolated 
enteropathogenic bacteria in this study. 
2.1.1 Salmonella spp.  
Salmonella spp. are a group of bacteria that reside in human beings’ intestinal tract and 
warm-blooded animals and can cause disease. It is a gram-negative rod that is a member of 
the Enterobacteriaceae. The genus Salmonella contains two species, including Salmonella 
enterica and Salmonella bongori [13]. Salmonella enterica is an important agent of 
foodborne illness. This species is sub-classified into six subspecies, of which S. enterica 
subspecies enterica is the most important for human health. The genus Salmonella can be 
subdivided into more than 2,400 serotypes. Salmonella enterica subsp. Enterica serotype 
Typhimurium (S. Typhimurium) and Salmonella enterica subsp. enterica serotype 
Serotypes are further subdivided by their resistance to bacteriophages (phage types or 
lystotypes), antibiotics or heavy metals; their biochemical characteristics (biovars or 
biotypes) or their sensitivity to or production of bacteriocins [13, 14]. Salmonella spp. are 
not particularly heat resistant. Most serotypes are killed by normal cooking conditions, i.e. 
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cooking to a core temperature of 75ºC instantaneously or an equivalent time-temperature 
combination, e.g. 70ºC for 2 minutes [14, 15].  
The majority of individuals recover without antibiotics from Salmonella infection within 
four to seven days. When diarrhea persists, people who are ill with a Salmonella infection 
should drink extra fluids. Treatment with antibiotics is prescribed for patients with serious 
illness, people with a compromised immune system, such as people with HIV infection or 
treatment with chemotherapy, adults over 50 years of age with medical issues, such as heart 
disease, babies (children under 12 months of age) and adults 65 years of age or older [16]. 
2.1.2 Shigella spp. 
Shigella are gram negative, nonmotile, facultatively anaerobic, non-spore-forming rods. 
Shigella are differentiated from the closely related E. coli based on pathogenicity, 
physiology and serology [17]. The genus is divided into four serogroups with multiple 
serotypes including A (S. dysenteriae, 12 serotypes), B (S. flexneri, 6 serotypes), C (S. 
boydii, 18 serotypes), and D (S. sonnei, 1 serotype). Infection is initiated by ingestion of 
shigella (usually via fecal-oral contamination). An early symptom, diarrhea (possibly 
elicited by enterotoxins and/or cytotoxin), may occur as the organisms pass through the 
small intestine [18].  
Shigellosis is endemic in developing countries were sanitation is poor. Normally, 10 to 20 
percent of enteric disease, and 50% of the bloody diarrhea or dysentery of young children, 
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can be characterized as shigellosis, and the prevalence of these infections decreases 
significantly after five years of life [18].  
People who are most likely to get Shigellosis including young children, but people of all 
ages are affected [19], travelers who travelled to developing countries, and to become 
infected with strains of Shigella bacteria that are resistant to necessary antibiotics [20], gay 
and bisexual men and other men who have sex with men who are more likely to acquire 
shigellosis than the general adult population [21], the person who has weakened immune 
systems due to illness (HIV) or medical treatment like chemotherapy for cancer can also 
get a more severe illness [22].  
2.1.3 Campylobacter spp. 
Campylobacters are defined as gram-negative rods that are motile, non-spore-forming, 
spiral or comma-shaped. They were originally assumed to be members of the genus Vibrio, 
but were assigned to the new genus, Campylobacter, in 1963 [23]. Campylobacter jejuni 
and Campylobacter coli, which account for most human Campylobacter isolates in the 
U.S., are both thermophilic. They grow best at 42 °C and microaerophilic, in that they grow 
best in an atmosphere containing 5% to 10% oxygen. Such optimum conditions of growth 
are likely to be a legacy of the evolutionary avian host and differ from the evolving 
Campylobacter spp. For instance, C. Upsaliensis, C. Concisus, C. hyointestinalis, C. fetus, 
C. ureolyticus, and C. lari, which have different reservoirs of animals and varying optimal 
conditions of development. 
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Campylobacter is a leading cause of bacterial diarrhea in developed countries, second 
to Salmonella as an agent of foodborne diarrheal illness in the United States [24] and the 
leading cause of foodborne bacterial illness worldwide, accounting for 96 million cases in 
2010 [25]. 
Most infections with Campylobacter are probably acquired by consuming raw or 
undercooked poultry or by eating something that has affected it. Other foods, including 
fish, meat and produce, are also transmitted by Campylobacter through contact with 
animals and by consuming untreated water. Typically, Campylobacter does not spread 
from one person to another. Campylobacter infection is prevalent in low-resource countries 
and people traveling abroad are more likely to become infected [26]. 
2.2 Diagnosis for Enteropathogenic Bacteria 
The standard operation procedure for stool culture was developed at Severance Hospital 
Laboratory Medicine, which referred to document code CM-PD-MM-16_7 version 7. 























Figure 1. Flowchart for stool culture [27] 
If the TSI property is  
-,+,-,+/-,+,+,+/-,+,+,- 
Sample received 
Sample condition verification (received or reject) 
Inoculation of specimen: 
MacConkey agar, Salmonella-shigella (SS) agar, Selenite broth (SB), 
Campylobacter (CF) 
Inoculate MacConkey thinly and inoculate SS, 
TCBS, and CF thickly. 
In May-October, inoculate 1/4 
compartment of TCBS medium. 
Inoculate 1/4 compartment of CF medium, put it in an 
anaerobic jar, keep it slightly aerobic (using an anaerobic box, 
O2 5%, CO2 10%, N2 85%) and incubate for 48 hours in a 42°C 
incubator. 
MacConkey agar: Two colonies of colourless and 
relatively different types are selected from one medium 
and inoculated into TSI. 
Processing and reading of stool culture 
Put the stool on the SB with a cotton 
swab and incubate it in a 35℃, CO2 
free incubator. 
Suspicion of Salmonella, 
serological method, and 
bacterial species identification 
with Bruker-MS, MALDI-TOF 
MS or VITEK 2 GN card, 
antibacterial susceptibility test 
with VITEK 2 N224 card, and 
additionally ciprofloxacin disc 
susceptibility test. Selected 
from one medium and 
inoculated into TSI. 
Suspicion of Yersinia, 
bacterial species 
identification with Bruker-
MS, MALDI-TOF MS or 
VITEK 2 GN card, and 
antimicrobial 
susceptibility test with 
VITEK 2 N224 card. 
If the TSI property is  
-,+,-,-/+,+,-,- 
If the TSI property is  
-,+,-,- 
Suspicion of Shigella, 
serological method and 
bacterial species 
identification with Bruker-
MS, MALDI-TOF MS or 
VITEK 2 GN card, 
antimicrobial susceptibility 
test with VITEK 2 N224 






2.3 Epidemiology and Antimicrobial Resistance of Enteropathogenic Bacteria 
Infectious diarrhea has different causes and incidence in different countries based public 
health level, lifestyle, and diet. Moreover, AMR’s rate is based on their health policy 
approach and the implementation to control it by each country or region.  
2.3.1 Epidemiology of Enteropathogenic Bacteria  
Enteric fever includes typhoid fever caused by Salmonella enterica subspecies enterica 
serovar Typhi (Salmonella Typhi) and Paratyphoid fever caused by Salmonella enterica 
subspecies enterica serovar Paratyphi (Salmonella Paratyphi) A, B, and C. Enteric fever is 
commonly found in Central Asia and South East Asia, and is also observed in other Asian 
countries, Africa, Latin America, and Oceania [28]. 
A study in USAM by NARMS were analyzed 20 Shigella isolates with decreased 
susceptibility to fluoroquinolones. Most patients (80%) from whom a travel history was 
obtained reported travel to South or Southeast Asia. Mutations within the quinolone 
resistance determining regions of gyrA and parC and plasmid-mediated resistance 
determinants (qnrB, qnrS, and aac(6′)-Ib-cr) were identified [29]. 
Another study in Northwest Iran has a surveillance for enterotoxigenic and 
enteropathogenic E. coli isolates from animal source foods in 2016. It revealed that the 
occurrence of E. coli was 45% in dairy and 52.5% in meat products. The milk without 
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pasteurization and traditional dairy products produced in unhygienic conditions are most 
likely the primary sources of E. coli pathotypes and other zoonotic pathogens. They can be 
considered a potential hazard to the health of the community [30]. 
Another investigation from stool culture in 2016-2017 at the Madibeng District of the 
North-West Province of South Africa indicated Campylobacter, Arcobacter spp., 
diarrhoeagenic E.coli, rotavirus and norovirus are among the givers of diarrhea in children 
younger than four years old [31].  
A diarrheal surveillance study in Cambodia in 2016 was observed multidrug resistance in 
10 (91%) of 11 Shigella isolates. One isolate was resistant to fluoroquinolones and 
cephalosporins and revealed decreased susceptibility to azithromycin. It found mutations 
in gyrA, parC, β-lactamase, and mphA genes. MDR increases concern about shigellosis 
treatment options [32]. 
STEC O157:H7 is the most common serotype that causes infections in humans worldwide; 
non-O157 STEC can also cause symptoms. In 2011, there were outbreaks of enteritis 
caused by STEC O104:H4 in Germany and France; of the 3,816 cases in Germany, 22% 
had hemolytic uremic syndrome [33, 34]. According to 20 years of epidemiological 
investigation of STEC O157:H7 in 1982-2002 in USA, hemolytic uremic syndrome was 
found in 4% of 8,598 cases, with mortality of 0.5% [35]. Although research on STEC has 
lacked in Korea, a previous report suggested that STEC was identified in 0.19% of 17,148 
diarrhea patients in Kwangju between 2004 and 2018 [36]. 
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In acute infectious diarrhea surveillance in Korea conducted by the KCDC, bacterial 
pathogens were isolated from 11.5 to 23.7% of samples between 2012 and 2016. In 2017, 
bacteria tested in the surveillance projected to (Salmonella spp., E. coli, Shigella spp., V. 
parahaemolyticus, V. cholerae, Campylobacter spp., C. perfringens, S. aureus, Bacillus 
cereus, L. monocytogenes, and Y. enterocolitica) were isolated in 1,376 of 9,344 samples 
collected at 70 participating institutions, thus at a rate of 14.7%,  indicated bacteria does 
not account for a high number of cases of acute diarrhea [1]. 
Korea has another surveillance system on gastrointestinal infections characterized by 
vomiting and diarrhea at 196 surveillance institutions including tertiary hospitals, hospitals 
with more than 200 beds, and public hospitals. Of the 15,717 pathogens isolated in 2017, 
9,276 cases were viral (59.0%), most of which were caused by norovirus and rotavirus, and 
6,373 were bacterial (40.5%) caused by Salmonella, C. perfringens, and Campylobacter; 
68 were caused by protozoa (0.4%), most of which were caused by Giardia lamblia [37]. 
The most common serotype of Salmonella in Korea between 1998 and 2007 was 
Salmonella Typhi, Salmonella enterica subspecies enterica serovar Enteritidis (Salmonella 
enteritidis), and Salmonella enterica subspecies enterica serovar Typhimurium 
(Salmonella Typhimurium) [38, 39].   Moreover, Salmonella causes food or water-borne 
gastroenteritis in Korea. Although its incidence is decreasing, typhoid fever introduced 
from other countries has increased due to increases in travels to other countries and foreign 
nationals living in Korea [38]. 
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2.3.2 Antimicrobial Resistance of Enteropathogenic Bacteria 
Salmonella, Campylobacter, Shigella, and STEC are the most common pathogenic bacteria 
causing acute bloody diarrhea. Multiple randomized controlled studies demonstrated that 
empirical antibiotic therapy in these patients lead to one day reduction in the duration of 
symptoms compared to placebo treatment. However, antibiotic treatment increases the time 
for excretion of Salmonella, and can also cause the excretion of fluoroquinolone resistant 
Campylobacter [40]. 
So that is why selection of antibiotics for empirical antibiotic therapy of acute infectious 
diarrhea should consider the distribution and antibiotic sensitivity of pathogens in local 
communities or areas where the patient traveled. Although fluoroquinolone antibiotics, 
including ciprofloxacin and levofloxacin, have been recommended for first-line therapy, 
resistance against these antibiotics has increased recently. Likewise, fluoroquinolone 
antibiotics have risks of severe side effects, such as ligament inflammation, ligament 
rupture, peripheral neuropathy, and central nervous system side effects, and thus require 
caution [40]. 
In some fields, macrolides, such as azithromycin, is recommended due to increased 
resistance of Campylobacter to fluoroquinolone. In Europe in 2012, Campylobacter 
infections were three times more common than nontyphoidal Salmonella infections [62], 
and ciprofloxacin resistance of Campylobacter was reported to be as high as 44% in some 
European countries [41]. Fluoroquinolone resistance of Campylobacter has also been 
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reported to be high in Mexico (56%) and Thailand (>92%) [42, 43]. Considering these, 
macrolides including azithromycin, may be considered for empirical antibiotic therapy in 
areas where Campylobacter is common and has high resistance to fluoroquinolone [40]. 
A study published in 2015 by Ghunaim et al. [44] found an erythromycin resistance of C. 
jejuni, relatively low. Only 8.6% of the isolates were resistant, while 63.2% were resistant 
to ciprofloxacin. A high rate of resistance to ciprofloxacin was also reported in the UAE, 
where 85,4% of the isolates were resistant [45]; in Poland, they were published [46] lower 
rates of resistance (40%) and only 2% in Australia [47]. 
According to the KCDC's study of 3,526 samples isolated from infectious diarrhea patients 
in 2014, Salmonella species accounted for 13.5%, and Campylobacter species accounted 
for 6.1% [48]. Moreover, 29% (63/218) of Campylobacter have been reported to be 
resistant to fluoroquinolones, although this report was made from a single institution [7]. 
Therefore, the percentage of Campylobacter and increase in fluoroquinolone resistance 
should be considered in infectious diarrhea in South Korea. The use of macrolides, such as 
azithromycin, should also be considered [40] . 
Azithromycin was more effective in decreasing the excretion of bacteria than ciprofloxacin 
in diarrhea observed in American soldiers deployed to Thailand; this finding seems to have 
been related to the high Campylobacter prevalence and fluoroquinolone resistance in the 
area [49]. Since antibiotic use increases recurrence and prolongs bacterial excretion in 
nontyphoidal salmonella, it is not recommended in most cases [50]. 
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In addition, KCDC studied 219 clinically isolated nontyphoidal Salmonella bacterial strains 
between 2006 and 2008, with resistance to ampicillin, nalidixic acid, ciprofloxacin, and 
TMP/SMX 49%, 50%, <1%, and 8%, respectively. The use of azithromycin, ciprofloxacin, 
or ceftriaxone is recommended for shigellosis [1]. A Korean study reported a high 
resistance rate, while trimethoprim-sulfamethoxazole or ampicillin may be used when 
isolated bacteria are susceptible. Resistance to trimethoprim, sulfonamide, nalidixic acid 
and ampicillin was 100%, 99%, 70%, and 49%, respectively in 67 Shigella sonnei strains 
isolated in the province of Jeollanam in 1999-2000, but no resistance to cefotaxime or 
ciprofloxacin was found [51].  
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III. MATERIALS AND METHODS 
3.1 Study Design 
A retrospective analysis was performed using existing data of stool culture from the 
patients hospitalized at Severance Hospital from 2011 to 2019. 
3.2 Microbiology Methods 
3.2.1 Sample Collection  
The stool samples were collected and placed it in transport mini sputum container. Bacteria 
to be cultured belong to Salmonella spp., Shigella spp., Plesiomonas shigellosides, Yersinia 
spp., Vibrio spp., and Campylobacter spp. (all spp. were included to Enterobacteriaceae).  
3.2.2 Bacterial Culture Media 
MacConkey agar base (BBL, USA), Salmonella Shigella agar (BBL), selenite broth (BBL) 
and Matrix (Bruker Daltonics, Germany) were used for Enterobacteriaceae. Thiosulfate 
citrate bile sucrose agar base (BBL) was used for Vibrio species. Campylobacter selective 
supplement (Oxoid), Campylobacter growth supplement (Oxoid) and blood agar base 





3.2.3 Bacterial Culture Incubation  
Enterobacteriaceae and Vibrio spp. cultures were incubated in aerobic condition at 35oC 
for 24 hours. For Campylobacter spp. cultures with specimen inoculated mediums were 
incubated in a microaerophilic atmosphere at 42 °C for 48 hours [52]. 
3.2.4 Bacterial Isolations and Identifications  
Colony shape, biochemical testing, MALDI-TOF MS, VITEK 2 ID card, and Bruker-MS 
were used for bacteria identification. Moreover, serological identification of Salmonella or 
Shigella was performed by using a slide aggregation reaction Salmonella and Shigella 
group diagnostic sera (National Health Research Institute). 
3.2.5 Antimicrobial Susceptibility Testing 
The anti-susceptibility testing (AST) was tested by VITEK 2 AST card, disc diffusion 
method and E-test following the Clinical Laboratory Standard Institute (CLSI) guideline 
[53]. A standardized 0.5 McFarland suspension was prepared, and VITEK® 2 cards 
(Biomerieux, Inc.NC, USA) for AST were inoculated following the manufacturer 
recommendation.  
For AST testing of Salmonella or Shigella were tested with VITEK 2 N224 card, and 
additionally ciprofloxacin disc susceptibility test. 
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Erythromycin, ciprofloxacin, and tetracycline discs were tested at the same time for 
Campylobacter species. 
3.2.6 Quality Control Methods 
Quality control of identification card and susceptibility test card is performed once a week 
or whenever the lot number of the kit is changed using the quality control strain. Bruker-
MS performs calibration once a week using the Bruker Standard. Antisera reagents are 
administered as standard or clinical strains once a month and when reagents are opened. 
Escherichia coli ATCC®a 25922 was used for quality control for each organism [53]. 
3.3 Data Registration and Statistical Analysis  
Data were entered into Severance Hospital Information Management System. Microsoft® 
Excel® 2010 (16.0.13328.20262) was used for statistical analysis.  
3.4 Ethical Considerations 
Ethical approval was granted from Yonsei Institutional Review boards No. 4-2020-1031 at 
the Severance Hospital, Yonsei University, Seoul, Republic of Korea. Patients were 
identified with a unique hospital number. No other data besides those noted in the routine 




4.1 Comparison of Trends in Isolation of Enteropathogenic Bacteria at a 
Tertiary-care Hospital 
There were 48,476 specimens were requested for stool culture from 2011 to 2109. Among 
the total requested specimens, 449 specimens were positive accounted to 0.9%. The 
enteropathogenic bacteria isolated from the stool culture during 2011 to 2019 were 
distributed as 270 (60.1%) Salmonella spp., 7 (1.6%) Shigella spp., 132 (29.4%) 
Campylobacter spp., 7 (1.6%) Vibrio parahaemolyticus, 1 (0.2%) Yersinia enterocolitica, 
and 32 (7.1%) others isolates.  
Salmonella spp. and Campylobacter spp. were the most common pathogen 60.1% and 
29.4%, respectively.  Followed by Salmonella spp., there were separated 4 (1.5%) 
Salmonella Typhi, 0 (0.0%) Salmonella Paratyphi-A, 111 (41.1%) Salmonella serogroup 
B, 82 (30.4%) Salmonella serogroup C, 63 (23.3%) Salmonella serogroup D, 5 (1.9%) 







Table 1. Comparison of trends in isolation of enteropathogenic bacteria at a tertiary-care 
hospital 
Characteristics 











No. of specimen cultured 13,412 37,846 51,441 60,714 48,476 
No. of positive specimen 1,732 3,503 2,140 648 449 
% of positive specimen 12.9 9.2 4.2 1.1 0.9 
No. of positive patient 1,677 3,182 1,531 565 449 
Salmonella Typhi 472 469 58 1 4 
Salmonella Paratyphi-A 18 101 3 2 0 
Salmonella serogroup B 3 245 564 86 111 
Salmonella serogroup C 4 108 126 89 82 
Salmonella serogroup D 5 107 341 157 63 
Salmonella serogroup E 2 32 55 22 5 
Salmonella other serogroup 0 40 39 2 5 
All Salmonella isolates 504 1,102 1,186 359 270 
Shigella subgroup A 16 5 2 0 0 
Shigella subgroup B 781 1,246 30 3 1 
Shigella subgroup C 8 43 0 0 6 
Shigella subgroup D 234 214 19 95 0 
All Shigella isolates 1,039 1,508 51 98 7 
Campylobacter spp. NT 185 239 85 132 
Yersinia enterocolitica NT 29 18 1 1 
Vibrio parahaemolyticus 45 96 42 27 7 
Plesiomonas shigelloides NT 4 11 0 0 
*Abbreviation: NT, not tested. 




4.2 Number of Patients with nontyphoidal Salmonella and Campylobacter spp.  
Isolation by Month in 2011-2019 
The findings were figured out of the number of patients with nontyphoidal Salmonella 
(NTS) and Campylobacter spp.  isolation by month in 2011-2019. Among 261 strains of 
NTS were positively identified in the month of August 43 (16.5%), September 40 (15.3%) 
and October 40 (15.3%). Moreover, 132 of Campylobacter spp. were positively identified 
in the month of June 15 (11.4%), July 18 (13.6%) and August 28 (21.2%).  (Table 2.) 
Table 2. Number of patients with nontyphoidal Salmonella and Campylobacter spp.  
isolation by month in 2011-2019 
Month 
No.  of patient with: 
Nontyphoidal Salmonella (%) Campylobacter spp. (%) 
January 12 (4.6) 5 (3.8) 
February 5 (1.9) 5 (3.8) 
March 14 (5.4) 14 (10.6) 
April 16 (6.1) 9 (8.6) 
May 21 (8.0) 9 (8.6) 
June 23 (8.8) 15 (11.4) 
July 26 (10.0) 18 (13.6) 
August 43 (16.5) 28 (21.2) 
September 40 (15.3) 8 (6.1) 
October 40 (15.3) 8 (6.1) 
November 12 (4.6) 4 (3.0) 
December 9 (3.4) 9 (6.8) 




4.3 Number of Patients with nontyphoidal Salmonella and Campylobacter spp. 
by Age Group 
The patient under 5 years and older than 60 years of age were found highly infected by 
NTS and Campylobacter spp. However, Campylobacter was isolated, not only under the 
age of 5 and more than 60 but also found highly infected at 10-19 and 20-29. (Table 3.) 
Table 3. Number of patients with nontyphoidal Salmonella and Campylobacter spp. by age 
group 
Organism 
No.  of patients by age group (year) 
≤5 6-9 10-19 20-29 30-39 40-49 50-59 ≥60 Total 
Nontyphoidal 
Salmonella 
118 27 24 9 10 11 18 44 261 
Campylobacter spp. 11 7 28 33 12 5 12 24 132 
 
4.4 Comparison of Trends in Antimicrobial Susceptibility of nontyphoidal 
Salmonella 
As shown in table 4, the susceptibility rate of NTS between 2011 and 2015 was ampicillin 
(53%), sulfamethoxazole-trimethoprim (93%), cefotaxime (92%), ceftazidime (92%), and 
fluoroquinolone (84%). Similarly, the susceptibility rate of NTS between 2016 to 2019 was 
ampicillin (51%), sulfamethoxazole-trimethoprim (85%), cefotaxime (74%), ceftazidime 








% of isolates susceptible to: 
AMP CHL SXT CTX CAZ FQN 
1979 - 1983 211 98 99 100 NT NT NT 
1984 - 1988 337 54 64 98 NT NT NT 
1989 - 1993 420 67 77 90 NT NT NT 
1994 - 1998 865 76 NT 90 98 98 100 
2001 - 2005 210 65 NT 93 99 100 100 
2006 - 2010 141 61 NT 92 96 98 98 
2011 - 2015 108 53 NT 93 92 92 84 
2016 - 2019 153 51 NT 85 74 81 73 
*FQN: ofloxacin (1994-1996), levofloxacin (1997-1998), levofloxacin (2001-2010) and levofloxacin (2011-
2019).  
*Abbreviation: AMP, ampicillin; CHL, chloramphenicol; SXT, sulfamethoxazole-trimethoprim; CTX, 
cefotaxime; CAZ, ceftazidime; FQN, fluoroquinolone; NT, not tested. 
*1969-2010 tables were adapted from reference [7]. 
4.5 Comparison of Trends in Antimicrobial Susceptibility of Campylobacter 
spp. 
As shown in Table 5, the rate of susceptibility to erythromycin and fluoroquinolone was 
87.03% and 25.4%, respectively, for Campylobacter spp.; they were isolated from 2011 to 
2015. On the other hand, the rates of susceptibility to erythromycin, fluoroquinolone and 
tetracycline were 98.2%, 15.8% and 51.4%%, respectively, for Campylobacter spp.; they 






Table 5. Comparison of trends in antimicrobial susceptibility of Campylobacter spp. 
Antimicrobial 
agents 






















Erythromycin 100 NT 92.0 95.1 87.2 87.03 98.2 
Fluoroquinolone NT NT 74.2 53.8 79.5 25.4 15.8 
Ampicillin 83.8 60.6 72.0 82.9 69.2 NT NT 
Cephalothin 0 7.9 8.8 4.9 7.7 0.0 NT 
Amikacin 86.2 86.3 98.2 97.6 94.9 NT NT 
Gentamicin 86.2 85.6 98.2 90.2 92.3 NT NT 
Tobramycin 82.8 84.1 77.8 85.4 92.3 NT NT 
Cotrimoxazole 64.3 19.2 22.1 4.9 7.7 NT NT 
Tetracycline 76.9 44.5 13.9 12.2 0 NT 51.4 
*Fluoroquinolones used: ofloxacin (1994-1996), levofloxacin (1997-1998), ciprofloxacin (2001-2010) and 
ciprofloxacin (2011-2019).  
*Abbreviation: NT, not tested. 
*1969-2010 tables were adapted from reference [7].  
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V. DISCUSSION  
In this study, we compared the results of the separation of enteropathogenic bacteria in 
2011-2019 with the results of separation in 1969-2010. Moreover, we analyzed the trend 
of enteropathogenic bacteria and examined the antibiotic resistance pattern. The number of 
requests for stool culture testing during this study period increased by 3.6 times compared 
to 13,412 samples from 1969-1978. The number of samples positive for culture decreased 
significantly from 1,732 (positive rate 12.9%) to 449 (positive rate 0.9%). Due to an 
increase in the number of patients with an increase in the number of beds, an increase in 
hospitalized infection monitoring culture, and improved health and hygiene [54]. Shigella, 
Vibrio, and Salmonella are mainly isolated among enterocolitis in developing countries, 
but Shigella and Salmonella Typhi are very rare in developed countries. In developed 
countries, Campylobacter and NTS became the major isolates. A USA study reported that 
42% of the enteritis bacterial causative agents were Campylobacter 32%, NTS 32%, and 
Shigella 13%, supporting the changes in these isolates [55, 56]. Another report regarding 
traveler diarrhea investigated tourisms from South East Asia countries including Thailand 
where commonly identified Campylobacter and Aeromonas [57]. 
Particularly, Salmonella enteritidis belonging to the Salmonella serotype D group, is one 
of the most common Salmonella serotypes prevalent all over the world and is known to be 
the main causative agent of foodborne salmonellosis [58]. During this study period, 2011-
2019, NTS was found in 261 patients, and it was the most isolated isolate, accounting for 
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58%. Salmonella isolated in 1969-1978, 472 (93.6%) were Salmonella Typhi, but in 2011-
2019, there were only 4 (1.5%) isolated. The number of Salmonella Paratyphi-A was 101 
(9.2%) in 1979-1988, but it decreased significantly to 0 (0.0%) in 2001-2010. On the other 
hand, NTS’s trend gradually increased and separated from 14 cases in 1969-1978 to 261 
cases in 2011-2019. In the past, there were many Salmonella serogroup B and D among 
NTS, but the isolates started to be decreased since 2010. Despite, compare to some 
developing countries were remained highly infected as a massive typhoid fever outbreak in 
Pakistan resulted in 5,372 extensively drug-resistant (XDR) Typhi cases stated during 
2016-2018, and five travel-related cases in the United States [59]. 
Shigella was the most common enteritis bacterium, accounting for more than 50% of the 
total number of isolates, separated from a total of 2,547 isolated in 1969-1988, but the trend 
decreased significantly after 1989. In this study, a total of 7 (1.6%) isolates were separated 
from 2011-2019. In the developing countries, there were many S. dysenteriae and S. 
flexneri infections, but in developed countries, there were many S. sonnei infections [60]. 
In the recent year, S. dysenteriae infection has been rare in Korea [61], the number of S. 
flexneri was the most prevalent until the late 1980s, and S. sonnei has been the most 
prevalent since 1990 [62]. Nonetheless, even after the late 1990s, it was decreased, Shigella 
infections often occurred, it is requiring continuous culture [62]. On the other hand, 
Thailand reported that the most commonly isolated Shigella species over the past two 
decades have been S. flexneri (79%) and S. sonnei (15%) and the incidence of S. sonnei 
were predominated over 80% in children under 5 in their country [63]. Even though, 
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Thailand is a developed country, Shigella remains highly infected by, if compare to South 
Korea’s current situation. 
C. jejuni is a major cause of bacterial diarrheal illness in the USA and in many other 
countries, with an estimated 845,000 foodborne cases per year in the USA alone, third in 
the number of estimated bacterial foodborne disease cases after Salmonella and 
Clostridium perfringens [60]. Severance Hospital began separating Campylobacter from 
1981 and was identified 239 isolates in 1989-1998, 83 isolates in 2001-2010 and 132 
isolates in 2011-2019. Among the 132 isolates of Campylobacter in 2011-2019, C. jejuni 
was the most common pathogen. By the way, a study in Cambodia found in multiplex PCR 
among 681 stool samples were 82 (12%) tested positive followed by C. jejuni in 66 samples 
and C. coli in 16 [64] with Campylobacter positive rates for Vietnam and Laos were below 
5% [65]. Thus, it showed that the rate of Campylobacter infection in developed country is 
higher than in developing countries. 
V. parahemolyticus was isolated 7 (1.6%) during the investigation period. The number 
was small because patients with this enteritis recovered naturally after 2-3 days of 
infection, so there was little opportunity to isolate the bacteria from tertiary medical 
institutions. In Korea, it is projected that the number of infected patients is high because 
they often reproduce fish and shellfish [66]. In fact, due to the food poisoning statistics 
from 2003-2016 from Korea Ministry of Food and Drug Safety in 2017, 225 cases and 
4256 patients were reported in outbreaks caused by V. parahaemolyticus, accounting for 
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5.8% of total outbreaks and 4.1% of total patients, respectively, based on all food-borne 
illnesses occurring in Korea [66].  
Some various studies have been reported Y. enterocolitica distribution, is mostly in 
Northern Europe and northern states of the USA, reflecting its increased growth at cold 
temperatures [67]. In Korea, have been reported 47 cases of Y. enterocolitica and 15 cases 
of P. shigelloides in 1979-1998 [54], but Y. enterocolitica was found in only one isolate 
during this study period. 
NTS and Campylobacter were highly isolated in patients under five years of age, similar 
to those of other domestic and foreign researchers [55, 68]. However, Campylobacter was 
isolated, not only under the age of 5 but also at 10-19 and 20-29. While infection with C. 
jejuni or C. coli can occur in patients of all ages [69], a recent study from Denmark showed 
that infection is more common in children (1 to 4 years) and young adults (15 to 24 years) 
than in other age groups [70] and slightly older patients (34.6 years versus 27.5 years) and 
those who traveled abroad were at a greater risk of being infected with C. coli than with C. 
jejuni [71]. Moreover, infections with C. jejuni and C. coli are more common during the 
summer months [70, 72]. Similarly, this study found that Campylobacter was positively 
identified in June, July, and August. 
In this study, NTS resistance to ampicillin and cotrimoxazole was higher than in the past. 
Furthermore, in the last four years in 2016-2019, the susceptibility rate in cefotaxime, 
ceftazidime and fluoroquinolone was decreased significantly. The generation of extended-
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spectrum β-lactamase (ESBL) resistant to third-generation cephalosporin in Korea was first 
reported in 2003. It had been increasing since then, presumably due to CTX-M-type ESBL 
[73, 74]. Even though, ciprofloxacin resistance rate has good activity against Salmonella; 
continuous monitoring is still necessary because Salmonella, which is resistant to 
ciprofloxacin, has increased in foreign countries [75]. KCDC analyzed NTS between 2006 
and 2008, reported the resistance to ampicillin, nalidixic acid, ciprofloxacin, and 
TMP/SMX was 49%, 50%, <1%, and 8%, respectively [51]. 
Erythromycin and ciprofloxacin are recommended for the treatment of C. enteritis, and 
recently increased resistance to these drugs has been reported. Although, it is difficult to 
make a direct comparison according to the change of the standard for analyzing the 
antimicrobial susceptibility test of Campylobacter, the ciprofloxacin susceptibility was 
79.5% in 2006-2010 [7], and the susceptibility was 25.4% in 2011-2015 and 15.8% in 
2016-2019. Thus, we observed the resistance rapidly increased. On the other hand, the 
erythromycin and tetracycline susceptibility in 2016-2019 were gradually decreased to 
98.2.% and 51.4%, respectively, compared to the previous period. In other studies in 
Europe in 2012, ciprofloxacin resistance of Campylobacter was reported to be as high as 
44% in some European countries [41]. Fluoroquinolone resistance of Campylobacter has 
also been reported to be high in Mexico (56%) and Thailand (>92%) [42, 43]. Despite, in 
Japan showed that macrolide resistance was in a low rate in C. jejuni and C. coli isolated, 
but resistant Campylobacter spp. were emerged to quinolones [76]. Considering these, 
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macrolides including azithromycin may be considered for empirical antibiotic therapy in 





This showed an increase in the incidence of enteropathogenic bacteria infection in 
Severance Hospital throughout the study. The pathogens with the most significant increase 
in incidence were non-typhoidal Salmonella and Campylobacter spp., even though there 
was a decrease in Salmonella Typhi and Shigella’s incidence. Enteropathogenic bacteria 
resistance to commonly prescribed antibiotics is steadily on the rise, as shown in this study. 
Non-typhoidal Salmonella resistance increased to ampicillin, sulfamethoxazole-
trimethoprim, cefotaxime, ceftazidime, and fluoroquinolone. Campylobacter resistance to 
fluoroquinolone increased significantly over the study period, but Campylobacter isolates 
remained susceptible to erythromycin. Continuous monitoring of resistant 
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